The association between SLC11A1 gene polymorphism and treatment failure of pulmonary tuberculosis
10.19485/j.cnki.issn2096-5087.2021.06.005
- Author:
LIU Yajie
;
ZHANG Yan
;
CHEN Yanggui
;
ZHANG Weisheng
;
MA Li
;
CAO Mingqin
- Publication Type:Journal Article
- Keywords:
pulmonary tuberculosis recombinant solute carrier family 11, member 1 gene polymorphism treatment outcome
- From:
Journal of Preventive Medicine
2021;33(6):563-567
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the association between recombinant solute carrier family 11, member 1 ( SLC11A1 ) rs17235409 polymorphism and treatment failure of pulmonary tuberculosis, so as to provide the basis for the prevention and treatment of pulmonary tuberculosis.
Methods:The patients with pulmonary tuberculosis registered for treatment at the Urumqi Center for Disease Control and Prevention in 2019 was recruited and collected demographic, clinical and treatment information from National Infectious Diseases Reporting System. The polymorphism of SLC11A1 rs17235409 was detected by multiple ligase chain reaction and Hardy-Weinberg balance test was performed. The multivariate logistic regression analysis was conducted for the association between rs17235409 and the treatment outcome of tuberculosis.
Results:A total of 731 cases of pulmonary tuberculosis patients were enrolled, and 37 cases failed, with a failure rate of 5.06%. The failure rate of the patients with G/A was 8.55%, with G/G was 4.23%. The results of multivariate logistic regression analysis showed that the patients with G/A were more likely to fail in the treatment than those with G/G ( OR=2.213, 95%CI: 1.041-4.702 ). The males with G/A were more likely to fail in the treatment than those with G/G ( OR=2.547, 95%CI: 1.021-6.356 ).
Conclusion:The rs17235409 polymorphism of SLC11A1 is associated with the failure of tuberculosis treatment, and the patients with G/A are more likely to fail.
- Full text:SLC11A1基因多态性与肺结核治疗失败的关联分析.pdf
